StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

Ovid Therapeutics cash

Cash and short-term investments held at the end of each period.

Ovid Therapeutics's cash was $169.77M at Jun 30, 2026. For fiscal 2025 it was $90.45M, up 70.4% from the year before. Over ten years it grew 2.6% a year on average. The highest annual figure on record is $187.80M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$90.45M+70.4%
FY2024Dec 31, 2024$53.08M-49.9%
FY2023Dec 31, 2023$105.83M-18.0%
FY2022Dec 31, 2022$129.00M-31.3%
FY2021Dec 31, 2021$187.80M+160.7%
FY2020Dec 31, 2020$72.03M-6.1%
FY2019Dec 31, 2019$76.70M+84.8%
FY2018Dec 31, 2018$41.50M-52.4%
FY2017Dec 31, 2017$87.13M+67.7%
FY2016Dec 31, 2016$51.94M-25.7%
FY2015Dec 31, 2015$69.94M+1343.1%
FY2014Dec 31, 2014$4.85M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$169.77M+342.7%
Q1 FY2026Mar 31, 2026$165.60M+285.1%
Q4 FY2025Dec 31, 2025$90.45M+70.4%
Q3 FY2025Sep 30, 2025$25.60M-59.2%
Q2 FY2025Jun 30, 2025$38.35M-50.2%
Q1 FY2025Mar 31, 2025$43.00M-52.4%
Q4 FY2024Dec 31, 2024$53.08M-49.9%
Q3 FY2024Sep 30, 2024$62.71M-28.0%
Q2 FY2024Jun 30, 2024$76.97M-20.2%
Q1 FY2024Mar 31, 2024$90.26M-23.3%
Q4 FY2023Dec 31, 2023$105.83M-18.0%
Q3 FY2023Sep 30, 2023$87.07M-36.8%
Q2 FY2023Jun 30, 2023$96.52M-36.7%
Q1 FY2023Mar 31, 2023$117.72M-30.2%
Q4 FY2022Dec 31, 2022$129.00M-31.3%
Q3 FY2022Sep 30, 2022$137.86M-31.7%
Q2 FY2022Jun 30, 2022$152.37M-28.2%
Q1 FY2022Mar 31, 2022$168.60M-27.7%
Q4 FY2021Dec 31, 2021$187.80M+160.7%
Q3 FY2021Sep 30, 2021$201.78M+132.3%
Q2 FY2021Jun 30, 2021$212.17M+414.3%
Q1 FY2021Mar 31, 2021$233.05M+299.7%
Q4 FY2020Dec 31, 2020$72.03M-6.1%
Q3 FY2020Sep 30, 2020$86.87M+129.2%
Q2 FY2020Jun 30, 2020$41.25M-12.9%
Q1 FY2020Mar 31, 2020$58.30M-2.2%
Q4 FY2019Dec 31, 2019$76.70M+84.8%
Q3 FY2019Sep 30, 2019$37.91M-27.8%
Q2 FY2019Jun 30, 2019$47.36M-24.3%
Q1 FY2019Mar 31, 2019$59.64M-19.6%
Q4 FY2018Dec 31, 2018$41.50M-52.4%
Q3 FY2018Sep 30, 2018$52.51M-45.3%
Q2 FY2018Jun 30, 2018$62.59M-41.0%
Q1 FY2018Mar 31, 2018$74.16M+67.7%
Q4 FY2017Dec 31, 2017$87.13M+67.7%
Q3 FY2017Sep 30, 2017$96.04M+66.3%
Q2 FY2017Jun 30, 2017$106.12M–
Q1 FY2017Mar 31, 2017$44.23M–
Q4 FY2016Dec 31, 2016$51.94M–
Q3 FY2016Sep 30, 2016$57.75M–

More Ovid Therapeutics figures

See a number that looks wrong?